Amgen Safety NET Foundation

The primary function of Amgen Safety NET foundation (the "foundation") is to provide poor, indigent and financially distressed patients with access to certain prescription drug therapies that they could not otherwise afford. The prescription drugs that the foundation distributes are products produced by Amgen inc. and its affiliates. Amgen inc. and its affiliates contribute all pharmaceutical products to ASNF at no cost. (Amgen inc. is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.) in particular, the foundation distributes aranesp, epogen, neulasta, n-plate, neupogen, prolia, xgeva, vectibix, corlanor, repatha, blincyto, kyprolis, imlygic, enbrel, parsabiv, aimovig, evenity, kanjinti, mvasi, avsola, riabni, lumakras, otezla, tezspire, amjevita, and imdelltra. During 2024, the foundation served 65,600 patients.